Immunic gets European patent for vidofludimus calcium

Immunic (IMUX) announced that the European Patent Office has granted a key European patent, EP3713554, directed to label-relevant dosing regimens of lead asset, nuclear receptor-related 1 activator, vidofludimus calcium. The patent is expected to provide protection for vidofludimus calcium in Europe into 2038, and may be eligible for a Supplementary Protection Certificate, which could extend market exclusivity potentially into 2043. This patent was previously granted by the United States Patent and Trademark Office in 2023. The claims broadly protect vidofludimus and its salt, solvate and free acid forms, in all label-relevant dosing regimens. This protection extends beyond a specific salt form, meaning that even alternative salts or forms will fall within the scope of the patent if used according to the label.